Navigation Links
Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells

LOS ANGELES (April 15, 2008) A common, naturally occurring virus that attacks cancer cells but appears to be harmless to normal cells is being studied as a possible treatment for malignant, highly aggressive and deadly brain tumors called gliomas. Researchers at Cedars-Sinai Medical Center are among a few in the United States evaluating this experimental therapy.

Over the course of a lifetime, most adults will be exposed to the virus in its natural state. It commonly infects the lungs and intestines but unlike most viruses causes few if any symptoms and is usually eliminated by the body within two weeks. But while the reovirus (respiratory enteric orphan virus) may be harmless to normal cells, it can specifically kill certain cancer cells.

Vulnerable cancer cells have a defect in a signaling pathway (the Ras pathway) that controls key cell functions. The reovirus is able to infect and kill cancer cells that have an activated Ras pathway, but the virus does not normally come into contact with cancer cells. Researchers at Oncolytics Biotech Inc., of Calgary, Canada, developed a therapeutic drug, REOLYSIN, from the reovirus and are conducting multicenter clinical trials for a variety of cancers. Cedars-Sinai is participating only in the study on recurrent gliomas, the most common and deadly brain cancers.

Based on the fact that many types of cancer cells have an activated Ras pathway, the company estimates that up to two thirds of all human cancers are susceptible to reovirus induced cell death .

Although not every glioma cell line has an activated Ras pathway, Ras activation is very common in these malignant brain cancers. In lab tests and animal studies, the reovirus appears to target Ras-activated tumor cells and leave normal cells alone, said neurosurgeon John S. Yu, M.D., director of Surgical Neuro-oncology at Cedars-Sinais Department of Neurosurgery. Yu is principal investigator of the REOLYSIN clinical trial at Cedars-Sinai.

According to the protocol of this open-label Phase I and II trial, patients will receive a single treatment of REOLYSIN, infused over 72 hours and directed into the tumor under sophisticated guidance. Expected length of hospital stay is about five days, and patients progress will be followed for at least 12 weeks.

Oncolytics published results of preclinical studies in the June 20, 2001 issue of the Journal of the National Cancer Institute. In an animal study, mice with gliomas that were treated with a single injection of reovirus survived significantly longer than untreated mice. Complete tumor regression was found in 20 of 23 mice treated with the virus.

In laboratory studies, widespread cell killing was seen in 19 of 24 established human glioma cell lines tested. Reovirus also infected and killed all nine of nine primary glioma cultures taken from brain tumor surgical specimens. Primary refers to gliomas originating in the brain, not metastasizing from other locations.


Contact: Sandy Van
Cedars-Sinai Medical Center

Related medicine news :

1. China Sky One Medical, Inc. Announces Its Successful Participation in the 20th International Medical Instruments and Equipment Exhibition
2. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
3. Roseland Medical Center Hosts Recognition Ceremony and Open House
4. Golden State Medical Supply Selects IBM Technology to Comply With California Prescription Drug Pedigree Regulations
5. Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club
6. Health Care Workforce Experts Available to Comment on IOM Report on Aging Baby Boomers and Impending Medical System Crisis
7. HHS Names First Director of the Biomedical Advanced Research Development Authority
8. Northwest Hospital & Medical Center Hosts Health & Wellness Pavilion At Second Annual King 5 Healthy Living Expo
9. VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System
10. Greenway Medical Technologies Experiences Continued Growth in OB/GYN Marketplace
11. Medical Records Institute (MRI) Develops Initiative for EMRs Supporting Medicolegal Requirements
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... are unfamiliar with. The article goes on to state that individuals are now more ... these less common operations such as calf and cheek reduction. The Los Angeles area ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. and SAN CLEMENTE, Calif. , ... California -based mobile pulmonary function testing company, is now able ... PFT devices developed by ndd Medical Technologies , Inc. ... testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® ... , can get any needed testing done in the comfort ...
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: